CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Clinical trials sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., explained in plain language.
Pharmaceutical manufacturer, subsidiary of CSPC Group.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New injection for high cholesterol begins first human safety tests Results expected Nov 2026 (estimated)
- New drug SYH2061 tested in healthy people for first time Results expected Nov 2026 (estimated)
- New schizophrenia shot could offer cheaper alternative to Brand-Name drug Results expected Dec 2026 (estimated)
- New injection aims to tackle stubborn high cholesterol and triglycerides Results expected Apr 2027 (estimated)
- New schizophrenia shot could offer cheaper alternative to abilify maintena Results expected Sep 2027 (estimated)
-
New injection aims to tackle hidden heart risk
Disease control Not yet recruitingThis Phase 2 trial tests an experimental injection called SYH2068 in 120 adults with high lipoprotein(a), a genetic risk factor for heart disease. Participants receive either the drug or a placebo to see if it safely lowers their Lp(a) levels over several months. The goal is to f…
Phase 2 • Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New hope for stubborn high blood pressure? phase 3 trial launches
Disease control Not yet recruitingThis Phase 3 trial tests aprocitentan, a drug already approved in some countries, for people with resistant hypertension—high blood pressure that stays high despite taking three or more medications. About 382 adults will receive either the drug or a placebo for 8 weeks. The main …
Phase 3 • Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New schizophrenia shot could offer cheaper alternative to abilify maintena
Disease control Not yet recruitingThis study compares a new injectable form of aripiprazole (SYH9096) to the approved drug Abilify Maintena® in 116 adults with stable schizophrenia. Participants receive five injections of each version, one month apart, to see if the new version reaches similar drug levels in the …
Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New shot could help lower stubborn high cholesterol
Disease control Not yet recruitingThis Phase 3 trial tests an injection called SYH2053 for people with high cholesterol that isn't controlled by standard pills. About 900 adults aged 18-75 will receive either the drug or a placebo, on top of their usual cholesterol medication. The main goal is to see if SYH2053 s…
Phase 3 • Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC